Compare New York Times Co (NYT) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Tenet Healthcare Corporation — how do they compare? New York Times Co trades at $66.6 (market cap $10.47B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Tenet Healthcare Corporation is the larger of the two by market cap, and New York Times Co pays a 1.42% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Tenet Healthcare Corporation for 15 Days on average.
| NYT | THC | |
|---|---|---|
Market Cap | $10.47B | $20.92B |
Volume | 1,998,850 | 455,764 |
Sector | Media | Health |
52-Week High | $85.86 | $280.77 |
52-Week Low | $54.66 | $161.37 |
Typical Hold Time | 81 Days | 15 Days |
Enterprise Value | $9.86B | $32.00B |
Dividend Yield | 1.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.60, up 3.95% over the past 24 hours, with a bearish technical signal. Recent earnings have consistently beaten expectations, with Q1 and Q2 2026 EPS exceeding forecasts. Revenue and net income have shown steady growth from 2022 to 2025, with margins improving. The company declared a quarterly dividend of $0.23 per share, payable in October 2026. Analyst consensus is a 'Hold' with a price target of $84.00, suggesting potential upside from the current price.
Outlook remains mixed; strong fundamentals and earnings beats support growth, but a shareholder lawsuit and bearish technical indicators present near-term risks. The stock offers a dividend yield, and institutional interest is present, but investors should weigh legal uncertainties and market sentiment against solid financial performance.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
